Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLC
Clinical trial NCT05448781 · UNKNOWN
Trial details
- NCT number
- NCT05448781
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-07-20
- Primary completion
- 2023-07-20
- Enrollment
- 38
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.